Abcam plc Announces Board Appointment
News Dec 13, 2014
Abcam plc has announced the appointment of Sue Harris as a non-Executive Director on the Abcam Board. Sue will join the Board with immediate effect and will Chair the Audit Committee.
A Chemist by training, Sue has over 30 years of financial and commercial experience. She began her career at Ford Motor Co. before moving to oil company Amerada Hess. Sue subsequently held senior executive roles at Marks & Spencer, across finance and latterly as Head of Corporate Development, and Standard Life where she led the process to float the company on the London Stock Exchange in 2006.
She then joined Lloyds Banking Group (LBG) where she was Finance Director of respectively; Cheltenham and Gloucester; LBG’s Retail Bank; and LBG Group Finance; and latterly Group Audit Director.
Sue is a Member of the Audit and Assurance Council of the Financial Reporting Council and previously was a Non-Executive Director on the Board of St. James’s Place (representing LBG) and a Member of the Audit and Remuneration Committee of the British Bankers’ Association.
She is Chair of Trustees for KCP Youth and during a ten year association with Mencap chaired both the Finance and Audit Committees. Sue has completed INSEAD’s Advanced Management Programme, is a Chartered Management Accountant and has a degree in Chemistry from Manchester University.
Murray Hennessy, Abcam Chairman commented: “I am delighted to welcome Sue to the Abcam Board. She brings a wealth of finance and commercial skills, which combined with her broad corporate experience and scientific background, make her an ideal person to further strengthen the Abcam Board at this exciting time in our journey.”
Protein's Role in Mitochondrial Metabolism IdentifiedNews
EXD2, a protein previously thought to be localised to the nucleus, has a key role in the production of proteins by mitochondria.READ MORE
Being Born During a Flu Pandemic May Increase Your Risk of Death During Another Flu PandemicNews
While past exposure to influenza A viruses often builds immunity to similar, and sometimes different, strains of the virus, researchers are calling for more attention to exceptions to that rule.READ MORE
Glythera Appoints Chief Scientific Officer and Strengthens SABNews
Dr Robert Lutz appointed as CSO to support development of next-generation PermaLink® Antibody Drug Conjugates. Dr Jon Roffey appointed to Scientific Advisory Board.READ MORE